Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724082 | 0.95 | ENPP2 (0.41) | ENPP2 | |
| SCHEMBL7077675 | 0.95 | ENPP2 (0.41) | ENPP2 | |
| SCHEMBL5723816 | 0.95 | ENPP2 (0.41) | ENPP2 | |
| SCHEMBL5724214 | 0.94 | ENPP2 (0.43) | ENPP2FAAHALDH1A1HPGD | |
| SCHEMBL5723792 | 0.89 | DPP8 (0.36) | TDP1ATMFAAHPLCG1ALDH1A1 | |
| SCHEMBL5724588 | 0.88 | FAAH (0.40) | TDP1ENPP2ATMFAAHCCR5 | |
| SCHEMBL5724203 | 0.87 | DPP8 (0.40) | TDP1ATMPLCG1ALDH1A1MAPT | |
| SCHEMBL5724526 | 0.87 | RAB9A (0.42) | TDP1ATMPLCG1ALDH1A1MAPT | |
| SCHEMBL5723744 | 0.85 | CHRM4 (0.37) | CHRM4TDP1ENPP2ATMCCR5 | |
| SCHEMBL5723847 | 0.84 | DPP8 (0.38) | CHRM4TDP1ENPP2ATMFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | CHRM4 1394/4885TDP1 3179/4885ENPP2 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.